*Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland †Department of Medical Genetics, University of Helsinki, Helsinki, Finland Departments of ‡Ophthalmology, Institute of Clinical Medicine, and §Internal Medicine, Clinical Research Center and Biocenter Oulu, University of Oulu, Oulu, Finland ¶Department of Clinical Chemistry, Oulu University Hospital, Oulu, Finland **Department of Biosciences, University of Helsinki, Helsinki, Finland.
Retina. 2013 Oct;33(9):1815-27. doi: 10.1097/IAE.0b013e318285cf92.
To study the association of single-nucleotide polymorphisms of interleukin 8, vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab treatment in exudative age-related macular degeneration.
Clinical records, smoking history, optical coherence tomography, and angiographies of 96 bevacizumab-treated exudative age-related macular degeneration patients were analyzed retrospectively. Blood DNA was collected. Based on the disappearance of intra- or subretinal fluid in optical coherence tomography, patients were graded as responders, partial responders, or nonresponders after 3 initial treatment visits and a median time of 3.5 months.
Interleukin 8 promoter polymorphism -251A/T was significantly associated with persisting fluid in optical coherence tomography. The A allele was more frequent in nonresponders than in responders (P = 0.033). In multivariate modeling, the AA genotype of -251A/T (P = 0.043) and occult (P = 0.042) or predominantly classic (P = 0.040) lesions predicted poorer outcome. Visual acuity change was better in responders than in nonresponders (P = 0.006). Baseline lesion size (P = 0.006) and retinal cysts after the treatment (P < 0.001) correlated with less visual acuity gain.
The A allele and the homozygous AA genotype of interleukin 8 -251A/T were associated with anatomical nonresponse to bevacizumab treatment.
研究白细胞介素 8、血管内皮生长因子、促红细胞生成素、补体因子 H、补体成分 C3 和 LOC387715 基因的单核苷酸多态性与渗出性年龄相关性黄斑变性对贝伐单抗治疗反应的关系。
回顾性分析了 96 例接受贝伐单抗治疗的渗出性年龄相关性黄斑变性患者的临床记录、吸烟史、光学相干断层扫描和血管造影。采集血 DNA。根据光学相干断层扫描中外或下视网膜积液的消失情况，将患者在 3 次初始治疗访视后和中位时间 3.5 个月时分为应答者、部分应答者或无应答者。
白细胞介素 8 启动子多态性-251A/T 与光学相干断层扫描中持续存在的液体显著相关。A 等位基因在无应答者中比在应答者中更为常见（P=0.033）。在多变量模型中，-251A/T 的 AA 基因型（P=0.043）和隐匿性（P=0.042）或主要经典型（P=0.040）病变预测结局较差。应答者的视力变化优于无应答者（P=0.006）。基线病变大小（P=0.006）和治疗后视网膜囊肿（P<0.001）与视力增益较少相关。
白细胞介素 8-251A/T 的 A 等位基因和纯合 AA 基因型与贝伐单抗治疗的解剖学无应答相关。
